$ cat ./records/gates-foundation-funds-76-million-gavi-china-hepatitis-b-vaccinat-2002.txt
Gates Foundation funds $76 million GAVI-China hepatitis B vaccination campaign
[RECORD.TXT] · cat --full
Between 2002 and 2007, GAVI — with major Gates Foundation funding — partnered with the Chinese government on a $76 million project to scale up hepatitis B vaccination in rural China. At the time China had one of the world's highest hepatitis B carrier rates, with over 10% of the population chronically infected. The campaign expanded vaccine coverage in the least-served rural provinces and helped shift national hepatitis B vaccination rates toward near-universal coverage, preventing an estimated 800,000 liver cancer deaths over subsequent decades.
Source: https://www.gatesfoundation.org/our-work/places/china
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Launched major HIV/AIDS prevention grant programs across sub-Saharan Africa totaling over $350 million
Next →
UN Secretary-General Kofi Annan praises Gates Foundation's 'visionary leadership'
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.